[Skip to Content]
[Skip to Content Landing]
Comment & Response
March 26, 2014

Use of Placebo in a Trial of Thalidomide for Pediatric Crohn Disease

Author Affiliations
  • 1Department of Pediatrics, University of Manitoba, Winnipeg, Canada
JAMA. 2014;311(12):1251. doi:10.1001/jama.2014.1275

To the Editor In a double-blind, placebo-controlled, randomized clinical trial (RCT), Dr Lazzerini and colleagues1 examined the effect of thalidomide vs placebo in children with active Crohn disease refractory to immunosuppressive medications. All immunosuppressive medications had to be stopped prior to recruitment and only tapering steroids were allowed during the study (ie, thalidomide or placebo was the sole treatment).

×